The WAVES study by Medtronic plc. Ordinary Shares (NYSE:MDT) which was focusing on VeClose U.S. pivotal clinical trial and one-year data has produced three-year outcomes. The VeClose U.S. pivotal clinical trial was evaluating the wellbeing and efficiency of the VenaSeal closure system alongside the Medtronic ClosureFast(TM) endovenous radiofrequency ablation (RFA) procedure.
The results of the trial, which enrolled 242 patients, were announced at the 2017 Charing Cross Symposium in London by Kathleen Gibson the M.D of Lake Washington Vascular in Bellevue, Wash
The trial concentrated on patients who were suffering from symptomatic refluxing great saphenous veins (GSV). At three years, the use of VenaSeal achieved a complete closure of GSV in 94.4% of patients treated with it while ClosureFast had 91.9% of patients. To say the least, the two presented non-inferior outcomes as well as durability, which is of the essence in every treatment.
Given that it was a randomized trial, which was expected to strengthen the reliable clinical performance of the two, Dr. Gibson says, “These long-term VenaSeal data along with post-market WAVES study results continue to build on the prior findings for this innovative treatment option for venous reflux disease, demonstrating safety, effectiveness, and quality of life.”
Medtronic also presented results for its IN.PACT Admiral™ drug-coated balloon (DCB). The one-year results compared standard usage patients (n=281) with a broader spectrum of patients (n=1125). Both groups displayed constant and affirmative outcomes with IN.PACT Admiral™. According to the system medical director for Vascular Services at OhioHealth Riverside Methodist Hospital, Gary Ansel, the IN.PACT Admiral™ DCB is safe and effective.
Medtronic’s commitment to developing evidence-based treatments
In the recent past, it has been partnering with leading scientists, clinicians and researchers in having solutions for complex PAD. The general manager of the Peripheral business, Mark Pacyna outlines that they have come a long way in their efforts to offer quality services that deliver clinical and economic value to healthcare consumers.
Medtronic provides work for more than 88,000 people is now gearing towards working in partnership with stakeholders around the world. In the meantime, Medtronic’s stock closed at $81.76 witnessing an increase of $1.11 or 1.38%.